Claims (7)
1. Farmaceutski pripravak, naznačen time što sadrži spoj formule 265:
ili njegovu farmaceutski prihvatljivu sol, stereoizomer, hidrat ili solvat, i farmaceutski prihvatljivo pomoćno sredstvo, gdje je farmaceutski pripravak u obliku kapsule, tablete, aerosola, otopine, suspenzije ili je formuliran za topikalnu primjenu.1. Pharmaceutical preparation, characterized in that it contains the compound of formula 265:
or a pharmaceutically acceptable salt, stereoisomer, hydrate or solvate thereof, and a pharmaceutically acceptable excipient, where the pharmaceutical preparation is in the form of a capsule, tablet, aerosol, solution, suspension or is formulated for topical application.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u liječenju poremećaja ili bolesnog stanja, gdje je aktiviranje ili inhibiranje receptora sfingozin-1-fosfata podtip 1 medicinska indikacija koju se bira iz skupine koju čine multipla skleroza, odbacivanje presatka, i sindrom dišnih tegoba kod odraslih.2. Pharmaceutical preparation according to patent claim 1, characterized in that it is intended for use in the treatment of a disorder or disease state, where the activation or inhibition of the sphingosine-1-phosphate receptor subtype 1 is a medical indication selected from the group consisting of multiple sclerosis, rejection graft, and respiratory distress syndrome in adults.
3. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 2, naznačen time što je poremećaj ili bolesno stanje multipla skleroza.3. A pharmaceutical preparation intended for use in accordance with claim 2, characterized in that the disorder or disease state is multiple sclerosis.
4. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 2 ili patentnim zahtjevom 3, naznačen time što se spoj ili njegova farmaceutski prihvatljiva sol, stereoizomer, hidrat ili solvat primjenjuje u dozi od otprilike 0,05 mg do otprilike 5000 mg.
[image]
,4. Pharmaceutical preparation intended for use according to claim 2 or claim 3, characterized in that the compound or its pharmaceutically acceptable salt, stereoisomer, hydrate or solvate is administered in a dose of about 0.05 mg to about 5000 mg.
[image]
,
5. Upotreba spoja formule 265:
[image]
,
ili njegove farmaceutski prihvatljive sol, stereoizomera, hidrata ili solvata, naznačena time što je spoj namijenjen pripravi medikamenta za liječenje poremećaja ili bolesnog stanja, gdje je aktiviranje ili inhibiranje receptora sfingozin-1-fosfata podtip 1 medicinska indikacija koju se bira iz skupine koju čine multipla skleroza, odbacivanje presatka i sindrom dišnih tegoba kod odraslih.5. Use of compound of formula 265:
[image]
,
or a pharmaceutically acceptable salt, stereoisomer, hydrate or solvate thereof, characterized in that the compound is intended for the preparation of a medicament for the treatment of a disorder or disease state, where the activation or inhibition of the sphingosine-1-phosphate receptor subtype 1 is a medical indication selected from the group consisting of multiple sclerosis, graft rejection and respiratory distress syndrome in adults.
6. Upotreba u skladu s patentnim zahtjevom 5, naznačena time što je poremećaj ili bolesno stanje multipla skleroza.6. Use according to claim 5, characterized in that the disorder or disease state is multiple sclerosis.
7. Oblik jedinice doziranja, naznačen time što sadrži spoj formule 265:
[image]
,
ili njegovu farmaceutski prihvatljivu sol, stereoizomer, hidrat ili solvat, gdje oblik jedinice doziranja sadrži od otprilike 0,05 mg do otprilike 1000 mg navedenog spoja zajedno s farmaceutski prihvatljivim nosačem po jedinici doziranja.7. Dosage unit form, characterized in that it contains the compound of formula 265:
[image]
,
or a pharmaceutically acceptable salt, stereoisomer, hydrate or solvate thereof, wherein the dosage unit form contains from about 0.05 mg to about 1000 mg of said compound together with a pharmaceutically acceptable carrier per dosage unit.